



January 19th 2023

Company name: FINDEX Inc
Name of representative: Teruo Aibara, President & CEO
(Securities code: 3649; PRIME Market)
Inquiries: Atsushi Fujita, Director and Head of Administration
(Telephone: +81-89-947-3388)

Notice of Preliminary Results on Product Implementations

Findex Inc. has received many inquiries from its shareholders and investors regarding the actual number of implementations for each product, and to respond to these requests from the market, it has been publishing preliminary implementation results (number of active users) of its products at the end of the second and fourth quarters of every fiscal year.

Following are the preliminary results of implementations per product as of December 31, 2022.

(As of 31st December 2022)

Product Name	Number of Users			
	University Hospitals	Other General Hospitals	Clinics and Others	Non-Medical Organizations
Claio Data Management Software	92 [+2]	422 [+11]	910 [+27]	—
DocuMaker Document Management Software for Medical Institutions	36 [+0]	124 [+2]	401 [+22]	—
C-Scan Software for Document Digitalization and Management	31 [+0]	111 [+3]	17 [+1]	—
PDI+ MoveBy Reference Information Management Software	25 [+0]	54 [+0]	8 [+1]	—
REMORA Electronic Medical Record	—	14 [+0]	800 [+18]	—
Cloud-Based Solutions for Medical Institutions	1 [+1]	0 [+0]	0 [+0]	—
DocuMaker Office Document & Public Document Management/e-Approval	2 [+0]	3 [+0]	0 [+0]	20 [+3]
Gateway System				648 Units [+3]
GAP/GAP-screener Gaze Analyzing Perimeter				35 Units [+9]

1. In order to provide preliminary figures on products that will serve as indicators of future business activities, changes have been made to the list of the products above.
2. Figures in [] indicate the increase or decrease from the previous announcement. For newly listed products, figures shown are the changes from the actual results as of June 30, 2022, as are those of other products.
3. Progress Note System C-Note and Nystagmus Examination Support System C-Nys are included in Claio in the above implementation results as options for Claio (they are not counted in duplicate).
4. Gateway system and GAP/GAP-screener are counted in terms of the number of units sold.

Note: This report is a translation of the press release of the Company prepared in accordance with the provisions set forth in the Securities and Exchange Law and its related accounting regulations. The original version of this press release is written in Japanese. In the event of any discrepancies in words, accounts, figures or the like between this press release and the original, the original Japanese version shall govern.